David Perlman is an Infectious Disease physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 Union Sq E
New York, NY 100033314
Telephone
212-844-8549Registry record last updated 29 Apr 2019.
Clinical trials
- HIV and Hepatitis Care Coordination in Methadone Treatment
Sponsor: University of California, San Francisco
- Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
61.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor17.9%Tivicay48%Dovato34%Isentress19%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor14.3%Triumeq61%Descovy20%Zidovudine19%Part D<11 patients+ 8 more classes in this area
Nervous system
20.8%gamma-Aminobutyric Acid A Receptor Positive Modulator6.7%Zolpidem Tartrate100%Part D<11 patientsBenzodiazepine3.4%Diazepam100%Part D<11 patients+ 4 more classes in this area
Cardiovascular
8.1%Statin2.7%Atorvastatin Calcium100%Part D<11 patientsThiazide diuretic2.7%Hydrochlorothiazide100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1994–2022 per NIH RePORTER. The latest:
- Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges
New York University
FY2022$255,976P30DA011041 - Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges
New York University
FY2021$255,982P30DA011041 - Ending HIV/AIDS among People Who Use Drugs: Overcoming Challenges
New York University
FY2020$244,267P30DA011041
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”